Drägerwerk AG & Co. KGaACapital Markets PresentationOctober, 2018

Interim financial reports as well as preliminaries are not audited.

Disclaimer

This presentation contains forward-looking statements regarding the future development of the Dräger Group. These forward-looking statements are based on the current expectations, presumptions, and forecasts of the Executive Board as well as the information available to it to date, and have been made to the best of its knowledge and belief. No guarantee or liability for the occurrence of the future developments and results specified can be assumed in respect of such forward-looking statements. Rather, the future developments and results are dependent on a number of factors; they entail risks and uncertainties beyond our control and are based on assumptions which could prove to be incorrect. Notwithstanding any legal requirements to adjust forecasts, we assume no obligation to update the forward-looking statements contained in this presentation.

This presentation does not constitute an offer of securities for sale or a solicitation of an offer to purchase any securities. No money, securities or other consideration is being solicited by this presentation.

2

Outlook

DrägerThe Company

Financials

3

protectDräger products

supportsave

lives,

and

.

4

Net sales developmentStrong growth independent of the global economy

Source: International Monetary Fund, World Economic Outlook Database

Net sales developmentDräger net sales in EUR million

Global gross domestic product

Stock-market crash

Stock-market crash

Stock-market crash

GulfWarGulfWarGulfWar

Mexican pesocrisis

Mexican pesocrisis

Mexican pesocrisis

Russianfinancial

crisis

Russianfinancial

crisis

Russianfinancial

crisis

Stock-marketcrash

Stock-marketcrash

Stock-marketcrash

IraqWarIraqWarIraqWar

Financialcrisis

Financialcrisis

Financialcrisis

5

DebtcrisisDebtcrisisDebtcrisis

2,500

2,000

1,500

1,000

500

0

3,000

1983

1984

1985

1986

1987

1988

1989

1990

1991

1992

1993

1994

1995

1996

1997

1998

1999

2000

2001

2002

2003

2004

2005

2006

2007

2008

2009

2010

2011

2012

2013

2014

2015

2016

2017

6

55%25%

20%

Africa, Asia, AustraliaEurope

Americas

Net Sales: EUR

~2.6 billionin 2017

70%

16%

14%

13,739employees

in 2017

Dräger-Sites21%

11%

10%

58%

Sales & Service Production, Quality,Logistics, Purchasing

R&D Administration

Production sites inEurope, America, Africa and AsiaSales and Service organizations worldwide

Safety~35 %

Medical~65 %

Dräger worldwideNet sales, sites and employees

MarketsOur customers

Fire services Oil and gas industry

Mining Chemical industry

Hospital

7

Other markets

8

Infinity Acute Care System Clincal software solutions Telemetry and IT-solutions

Medical supply units Medical Gas supply

systems Medical lights and video

solutions

Consumables and accessories

Classical-, Multivendor product service, Professional Service

Training

Anaesthesiology

Ventilation

Thermoregulation

Patient Monitoring & Clinical IT

Workplace Infrastructure

Hospital Consumables & Service

Intensive Care Operating Room Neonatal Care Hospital wideSolutions

Note: Market position based on Dräger‘s market knowledge and its own assessment of market position; positions ranked according to net sales.

Anaesthesia workstations and vaporizers

#1 in Europe and #2 in the US market

Emergency & Transport-, Neonatal- and Intensive Care ventilators

Respiratory monitoring #1 in Europe

Incubators and Warming Therapy

#2 worldwide and #1 in Europe

9

Breathing Systems

Gas Detection Systems

Personal Protection Equipment

Impairment Check Equipment

Engineered Solutions

Service

Fixed and mobile gas detection systems

#1 worldwide and #1 in Europe

Alcohol- and drugscreening devices

Interlock devices #1 worldwide and

#1 in Europe

Protection equipment for hazardous working environments

Body and Head protection, rescue and escape devices, Masks and Filters, etc.

Self-containedBreathing Appartus forfire fighters

#2 worldwide and #1 in Europe

Customer specific solutions

mobile and stationary firefighting training systems

Rescue chambers

Spareparts and consumables

Product Service Rental, On-site shops

and Shutdown Service Marine-Offshore Service

Note: Market positions based on Dräger‘s market knowledge and its own assessment of market position; positions ranked according to net sales.

Fire Service

Oil & Gas Chemical Mining Other Markets

10

Medical and safety technology providing long-term growth prospects in developed and emerging markets

Hospital

Attractive growth prospects in sizeable markets …

… in developed markets…

… as well as in emerging markets

Oil&Gas Chemical Mining FireService

Average expected annual market growth for the global medical equipment market significantly exceeding growth in many other sectors

Strong growth prospects in both developed and emerging markets

Very diversified markets with numerous product and service offerings

Attractive growth prospects for target sectors (e.g. industry) and growing safety investments

Rapidly aging population and consequently increasing healthcare expenditure

Increasing demand for medical equipment to improve clinical workflows and efficiency

Increasingly stricter safety regulations Rising environmental awareness Improved outlook for target markets

Strong growth of GDP and population resulting in a demand for improved medical services

Political benefits from investments in health care sector

Increasingly higher safety standards Increasing industrial hygiene awareness Strong growth of key customer sectors

11

Management of innovation rate through continuous improvements in quality and R&D processes

Expansion of market positions in attractive markets. Special focus on profitable growth in developing countries

Expansion of service and consumables business

Investments for future growth

1

2

3

4

Strategy for profitable growth

12

1

Strong R&D focus Innovation to enhance future growth (examples)

Approximately 1,300 employees in R&D around the globe.

EUR 235 million spent for R&D activities in 2017 (9.1 % of net sales).

Certified test-center at Lübeck headquartersupports innovation- and approval process.

Qualitymanagement organization with >100 employees.

Very close collaboration with customers to develop new and improve existing products.

Technological competency and high quality standards result in leading market positions and high barriers to entry.

Technology and innovation leadership to drive profitable growth

Babyleo ®

Incuwarmer: combination of a

classical incubator and warming bed

functionalities.

Oxylog® VE300

Lightweight, ergonomic designed emergency ventilator for ambulance, ER and clinical patient

transport.

Dräger X-am® 8000

Multigas detector for measurement of

up to 7 gases simultaneously.

Note: no meaningful capitalization of R&D budget

13

Investments in profitable

growth in developing countries

2

Focus on the specific needs of customer in developing countries Identify growth potential in strong growing markets like China, Brazil and India Capitalize on the significant investments into the Sales & Service infrastructure and

specific market knowledge, especially in our Regions Asia / Pacific, Central- and South-America

Enhance engagement with partners in developing countries to expand local presence with R&D, manufacturing, sales and after sales business

2

Net sales 2017

Developed Markets

77 %

Newly industrialized

countries23 %

Focused product range

Exploit growth potentials in developing countries

Fabius Plus XLVista 120Savina Color

14

Further expansion of service and

consumables business

3

Service- and consumables business a clear focus of our Sales activities

3

Dräger Services Dräger Consumables

Functionalities with added value, e.g. optimizing workflow with RFID-based communication between consumables part and therapy machine

Dräger quality to improve hygienic standards Dräger value add especially in development of

consumables. Production usually via suppliers Partly proprietary consumable products, e.g. Dräger-Tubes

Globally over 3,000 service technicians Fast and reliable service (repairs and spare parts) is a

critical factor for customers Dräger Service technicians important for customer loyalty Efficient service solutions via remote service Broad offerings of product service New services in the areas of Rental, Multi-Vendor and

Marine-offshore

Capitalize on large installed base to expand after sales business Focus on combined sale of equipment and after sales contracts Expansion of disposable consumables business

Investments 2018/2019 will support future growth…

15

WE ARE INVESTING IN … WE WILL ACHIEVE …

… increasing sales resources

&-capabilities

… acceleratingR&D

roadmap

Strengthening Safety sales channels FGDS System Centers Key Account Management Digital distribution channels Global roll out of Future Technician Workplace

More R&D resources (focus on SW-development)

Partnership with external development partners Accelerate EM product portfolio

…a strengthened sales force to support bringing the innovation road map to market.

…major product releases in 2020, 2021 and 2022.

SG&A2018/19~30%

SG&A>2020<30%

MedicalInnovationrate 2017

26%

MedicalInnovationrate 2020

>28%

…and will lift EBIT margin again from 2020

4

Financials

16

Business developmentDräger Group 5y view

17

Note: restructuring charges included in FY EBIT: EUR 35 million in 2015, EUR 10 million in 2016Dräger Value Added (DVA) = EBIT less cost of capital of average invested capital

2013 9M 2017 9M 2018

€ million € million

Net Sales 1,729.1 % growth -0.5%% growth (FX adjusted) 3.0%

Gross margin 42.4%

Functional Expenses -771.4 % of Net Sales -44.6%

EBIT -41.0 EBIT Margin -2.4%

DVA -16.1

2.5%

67.0

1,737.0 1.9%2.4%

44.7%

-730.3 -42.0%

43.5

-999.2 -39.6%

136.9 5.4%

2014

€ million

2,434.7 2.5%

2016

€ million

2,523.8 -3.3%-1.5%

45.0%

4.0%

46.7% 44.9%

66.7 2.6%

49.8 81.6

-967.8

7.3%

-46.3

-1,098.4 -42.1%

178.6

-39.7%

2,374.2 0.0%3.1%

48.3%

200.8 8.5%

113.9

-942.2 -39.7%

€ million

2015

€ million

2,608.9 7.2%2.9%

2017

€ million

2,572.3 1.9%3.3%

44.8%

-992.0 -38.6%

155.7 6.1%

70.7

Key figuresDräger Group 5y view

18

Note: Investments 2015 include EUR ~60m for M&A

9M 2017 9M 2018

€ million € million

Cashflow (from operating activities) -42.0

Investments 54.0

Cash and cash equivalents1 135.8

Net financial debt1 69.3 Net financial debt 1 /EBITDA 2 0.44

Capital employed 1 1,283.4 ROCE (EBIT 2 /Capital employed 1) 5.6%

Net Working Capital1 616.8 1 Values as of reporting date2 EBITDA and accordingly EBIT of the last twelve months

78.5

63.7

200.4

16.1 0.07

1,213.7 12.6%

537.7

34.7 0.16

1,247.0 11.0%

563.2

2014

€ million

195.3

99.9

221.5

2016

1,269.3 5.3%

582.3

296.9

10.7

539.4

2015

€ million€ million

188.0

124.7

110.0 0.4

1,052.9 19.1%

524.3

2013

€ million

68.3 39.9

196.9

172.8

145.3 0.96

110.6

232.1

0.04

1,107.2 16.1%

1,243.6 12.5%

557.2

2017

€ million

143.3

106.2

247.6

-29.2 -0.12

Outlook

19

20

Outlook

Note: Dräger Value Added (DVA) = EBIT less cost of capital of average invested capitalAdditional forecast figures in the appendix on page 25

EXPECTATIONS FOR FISCAL YEAR 2018

2017 2018e

Net sales 3.3%(net of currency effects)

+2.0 - +5.0 %(net of currency effects)

EBIT margin 6.1% 2.0 - 3.5 %

Dräger Value Added EUR 70.7 million EUR -40 - 0 million

Guiding philosophyWhat we stand for

21

22

Dräger management

Fifth generation of the Dräger family to lead the company

Chairman of the Executive Board (Chief Executive Officer)

At Dräger since 1992

Stefan Dräger

Vice Chairman of the Executive BoardExecutive Board member for Finance and IT

At Dräger since 2008

Gert-Hartwig Lescow

Executive Board member for Purchasing, Production and Logistics

At Dräger since 2015

Rainer Klug Dr. Reiner Piske

Executive Board member for Human Resources

At Dräger since 2015

Executive Board member for Innovation and Quality

At Dräger since 2010

Anton Schrofner

Responsible for the Americas region

Responsible for the Europe region

Responsible for the Africa, Asia and Australia regions

23

24

Shareholder structure

ShareholdingCommon shares

67.2 %

28.8%

4.0%

Dr. Heinrich Dräger GmbHFree floatMembers of the Dräger family

10,160,000 common shares (28.8 % free float)7,600,000 preferred shares (100.0 % free float)

ShareholdingDr. Heinrich Dräger GmbH

Stefan Dräger GmbHDräger FoundationSuccessors of Dr. Heinrich Dräger

58.7%

23.2%

18.1%

Guidance 2018

25

EXPECTATIONS FOR FISCAL YEAR 2018

2017 2018e

Net sales 3.3%(net of currency effects)

+2.0 - +5.0 %(net of currency effects)

EBIT margin 6.1% 2.0 - 3.5 %

Dräger Value Added EUR 70.7 million EUR -40 - 0 million

Other forecast figures:

Gross margin 44.8 % 42.5 - 44.0 %

Research and development c EUR 234.7 million EUR 245 - 260 million

Interest result EUR -12.8 million Slight improvement

Days working capital (DWC) 111.7 days on prior year's level

Investment volume EUR 106.2 million EUR 85 - 100 million*

Net financial debt EUR -29.2 million Slight deterioration

*excluding company acquisitions

2013 2014 2015 2016 2017SEGMENT EUROPEOrder Entry 1 € million 1,322.4 1,357.0 1,391.0 1,382.5 1,447.8Net Sales 1 € million 1,333.5 1,362.2 1,420.7 1,384.3 1,415.5EBIT € million 131.2 128.5 59.4 84.5 108.1EBIT margin % 9.8 9.4 4.2 6.1 7.6

SEGMENT AMERICAOrder Entry 1 € million 465.2 461.5 496.8 515.0 509.2Net Sales 1 € million 458.7 471.2 509.1 503.7 510.4EBIT € million 8.5 -0.4 -18.6 10.3 4.0EBIT margin % 1.8 -0.1 -3.7 2.0 0.8

SEGMENT AFRICA, ASIA, AUSTRALIAOrder Entry 1 € million 597.0 597.0 644.5 641.2 657.6Net Sales 1 € million 581.9 601.3 679.1 635.8 646.4EBIT € million 61.2 50.5 25.8 42.1 43.7EBIT margin % 10.5 8.4 3.8 6.6 6.8

1 years 2012–2014 were adjusted pro-forma due to the change in segment reporting.

Business Development Segments 5y view

26 For further analysis, this data (including quarterly figures) can be downloaded as an Excel file from the Dräger website

Business development Q3Segments

27

Europe Americas Africa, Asia, Australia Dräger GroupQ3 2017 Q3 2018 Q3 2017 Q3 2018 Q3 2017 Q3 2018 Q3 2017 Q3 2018

€ million € million € million € million € million € million € million € million

Order entry 343.2 341.9 120.4 135.1 162.7 180.4 626.3 657.4

Net Sales 342.4 339.3 117.1 116.6 161.5 157.3 621.0 613.3

EBITDA 33.3 22.8 -0.1 -7.4 12.6 0.7 45.7 16.2

EBIT 23.0 12.9 -5.5 -12.8 6.9 -4.6 24.4 -4.4

EBIT-margin 6.7 3.8 -4.7 -11.0 4.3 -2.9 3.9 -0.7

Capital Employed1 565.6 587.5 284.2 310.8 364.0 385.2 1,213.7 1,283.4

ROCE1,2 17.9 15.5 3.4 -10.5 11.5 3.3 12.6 5.6

DVA 61.8 50.9 -11.2 -53.3 16.4 -13.7 67.0 -16.1 1 Values at due date2 EBIT of the last twelve months

Business development 9MSegments

28

Europe Americas Africa, Asia, Australia Dräger Group9M 2017 9M 2018 9M 2017 9M 2018 9M 2017 9M 2018 9M 2017 9M 2018

€ million € million € million € million € million € million € million € million

Order entry 1,050.0 1,048.5 379.5 363.2 498.9 519.5 1,928.3 1,931.2

Net Sales 960.7 984.1 344.7 317.7 431.5 427.3 1,737.0 1,729.1

EBITDA 72.3 56.1 6.6 -29.7 27.0 -4.4 105.8 22.0

EBIT 42.3 25.4 -9.4 -46.0 10.6 -20.5 43.5 -41.0

EBIT-margin 4.4 2.6 -2.7 -14.5 2.5 -4.8 2.5 -2.4

Capital Employed1 565.6 587.5 284.2 310.8 364.0 385.2 1,213.7 1,283.4

ROCE1,2 17.9 15.5 3.4 -10.5 11.5 3.3 12.6 5.6

DVA 61.8 50.9 -11.2 -53.3 16.4 -13.7 67.0 -16.1 1 Values at due date2 EBIT of the last twelve months

Business Development medical and safety products 5y view

29

For further analysis, this data (including quarterly figures) can be downloaded as an Excel file from the Dräger website

2013 2014 2015 2016 2017MedicalOrder Entry € million 1,559.3 1,569.8 1,646.0 1,662.6 1,683.7Net Sales € million 1,545.2 1,577.2 1,698.8 1,647.4 1,668.0EBIT € million 126.1 107.6 46.2 85.3 92.9EBIT margin % 8.2 6.8 2.7 5.2 5.6

SafetyOrder Entry € million 825.3 845.7 886.2 876.1 931.0Net Sales € million 829.0 857.5 910.1 876.5 904.3EBIT € million 74.7 71.0 20.5 51.6 62.8EBIT margin % 9.0 8.3 2.2 5.9 6.9

Business developmentMedical

Q3 2017 Q3 2018 9M 2017 9M 2018€ million € million € million € million

Order entry 412.4 427.8 3.7 6.2 1,253.4 1,242.9 -0.8 2.8

Europe 210.0 206.6 -1.6 0.3 624.7 619.1 -0.9 0.6

America 84.0 95.7 13.8 19.0 265.5 249.2 -6.1 2.0

Africa, Asia, Australia 118.4 125.5 6.0 7.6 363.2 374.6 3.1 7.2

Net Sales 399.9 376.0 -6.0 -3.8 1,106.3 1,080.2 -2.4 1.1

Europe 202.4 195.0 -3.6 -2.2 564.2 571.8 1.3 2.7

America 83.2 77.1 -7.3 -3.2 233.4 212.8 -8.8 -1.0

Africa, Asia, Australia 114.3 103.9 -9.1 -7.0 308.6 295.6 -4.2 -0.3

EBIT 9.1 -14.0 > -100 4.7 -56.2 > -100

EBIT-margin (%) 2.3 -3.7 0.4 -5.2

Change% (FX adj.)

Change% %

Change% (FX adj.)

Change

Business developmentSafety

Q3 2017 Q3 2018 9M 2017 9M 2018

€ million € million € million € million

Order entry 213.9 229.7 7.4 10.4 674.9 688.3 2.0 5.7

Europe 133.2 135.3 1.6 3.9 425.3 429.4 1.0 3.0

America 36.3 39.5 8.6 13.9 114.0 114.0 0.0 8.7

Africa, Asia, Australia 44.3 54.9 23.9 27.3 135.6 144.9 6.8 11.5

Net Sales 221.1 237.3 7.3 10.3 630.7 648.9 2.9 6.5

Europe 140.0 144.3 3.1 5.5 396.5 412.2 4.0 6.0

America 33.9 39.6 16.8 21.7 111.3 104.9 -5.8 2.0

Africa, Asia, Australia 47.2 53.4 13.0 16.5 122.9 131.7 7.2 12.0

EBIT 15.2 9.6 -37.0 38.8 15.1 -61.0

EBIT-margin (%) 6.9 4.0 6.1 2.3

Change

% (FX adj.)

Change

%

Change Change

% % (FX adj.)

Functional expenses5y view

32

9M 2017 9M 2018

€ million € million

R&D 191.6 % of Net Sales 11.1%

SG&A 581.7 % of Net Sales 33.6%

Other operating income -1.9

Functional Expenses total 771.4 % of Net Sales 44.6%

Headcount1 14,2331 Values as of reporting date

13,642

171.7 9.9%

556.1 32.0%

2.5

730.3 42.0%

2016

€ million

-219.0 -8.7%

-212.0

-30.8%

-967.8 -39.7%

€ million

2014

-8.7%

-749.2

€ million

-201.5 -8.5%

-738.4 -31.1%

-942.2

2013

-231.1 -8.9%

2015

€ million

-39.6%

-2.2 -6.6 -6.1 -18.1

-999.2

13,334 13,737 13,936 13,263

-861.2 -33.0%

-1,098.4 -42.1%

-762.1 -30.2%

-39.7%

-764.0 -29.7%

6.7

-992.0 -38.6%

13,739

2017

€ million

-234.7 -9.1%

Cash-flow statement

33

9M 2017 9M 2018€ million € million

Group net profit 119.9 104.7 33.3 81.7 98.5 24.5 -34.7

Change in inventories -36.5 -1.2 -5.4 17.4 -30.0 -84.4 -132.8

Change in receivables -69.5 1.6 -44.6 31.3 -22.4 109.2 98.4

Change in payables 6.4 25.2 -22.8 -10.2 22.2 -10.9 -14.3

Depreciation and amortization 69.0 77.0 84.2 85.8 84.2 62.4 63.1

Other operating cash flow items -31.1 -19.3 -4.8 -10.6 -9.3 -22.3 -21.7

Operating cash flow 68.3 188.0 39.9 195.3 143.3 78.5 -42.0

Investing cash flow -86.5 -102.6 -167.0 -77.3 -65.5 -48.8 -44.1

Free cash flow -18.2 85.4 -127.1 118.1 77.8 29.7 -86.1

Financing cash flow -70.8 -26.3 -1.3 -70.0 -41.9 -43.0 -23.4

Change in cash1 -88.9 59.0 -128.4 48.1 35.9 -13.3 -109.5

Cash and cash equivalents2 232.1 296.9 172.8 221.5 247.6 200.4 135.8 1 Change in cash and cash equivalents, i.e. without any effect of exchange rates2 Values as of reporting date

€ million€ million€ million € million20152013 2014 2016 2017

€ million

Consolidated balance sheet

34

31 Dec 2016 31 Dec 2017 Change€ million € million %

Intangible Assets 347.6 342.5 -1.5 Property, plant and equipment 420.9 432.3 2.7 Other noncurrent assets 150.1 154.0 2.6 Noncurrent assets 918.6 928.8 1.1

Inventories 386.8 387.7 0.2 Trade receivables 681.7 669.2 -1.8 Other current assets 103.8 121.1 16.7 Cash and cash equivalents 221.5 247.6 11.8 Current assets 1,393.8 1,425.5 2.3

Total assets 2,312.3 2,354.4 1.8

Consolidated balance sheet

35

31 Dec 2016 31 Dec 2017 Change€ million € million %

Equity 1,003.5 1,068.3 6.5

Liabilities from participation certificates 22.7 23.8 4.7 Provisions for pensions and similar oblig 318.3 313.0 -1.7 Noncurrent interest bearing loans 188.6 137.8 -27.0 Other noncurrent liabilities 108.6 114.0 5.0 Noncurrent liabilities 638.2 588.6 -7.8

Current Provisions 211.2 195.1 -7.6 Current loans and liabilities to banks 57.0 71.5 25.4 Trade payables 179.8 202.9 12.9 Other current liabilities 222.6 228.0 2.4 Current liabilities 670.6 697.4 4.0

Total equity and liabilities 2,312.3 2,354.4 1.8

36

Earnings per share

+

=

* tax benefit arises from the tax deductible pay-out to the PCs; please refer to Annual Report 2017, note 19** without minimum dividend (as interest, the minimum dividend is already included in net earnings)** the EPS is not calculated in accordance with IAS 33 PCs = participation certificates (Genussscheine)

2015 2016 2017Net profit (less the share of earnings attributable to non-controlling interests)

'000 € 33,575 81,391 98,530

Scenario: 100% pay-out ratio 100% 100% 100%tax benefit from pay-out to PCs* '000 € 3,188 7,888 9,493Earnings attrib. to shares and PCs (incl. tax benefit) '000 € 36,763 89,279 108,023 100%

Earnings attributable to PCs** '000 € 11,719 28,425 34,420 32%Earnings attributable to shares '000 € 25,044 60,855 73,603 68% EPS (common share) € 1.40 3.40 4.12 EPS (preferred share) € 1.46 3.46 4.18

Scenario: actual/proposed pay-out ratio 12.9% 5.3% 11.6%tax benefit from pay-out to PCs* '000 € 340 341 960Earnings attrib. to shares and PCs (incl. tax benefit) '000 € 33,915 81,732 99,490 100%

Earnings attributable to PCs** '000 € 1,249 1,236 3,482 3%Earnings attributable to shares '000 € 32,665 80,496 96,008 97% EPS (common share)*** € 1.83 4.51 5.38 EPS (preferred share)*** € 1.89 4.57 5.44

Selection of new products 2017

MEDICAL SAFETY

IACS VG6/VG7 Vista 120 S

Movita® Lift Strong Savina® 300 Select

Secor ® 7000

Dräger-Tubes App Dräger Alcotest® 5000

Pulsar 7000

37

Oxylog® VE300 Dräger X-am® 8000

38

Innovation rate

Share on new products and upgrades medical1

1 Launched in the last 3 years; products are regarded as new, if they enable Dräger to either enter a new market segment or if products are regarded as completely new according to Dräger‘s customers and Dräger‘s sales force. Upgrades are those products, which serve existing Dräger markets, but their functionality is perceived as significantly enhanced by Dräger‘s customers and Dräger‘s sales force.

New productsUpgrades

Net sales

0%

5%

10%

15%

20%

25%

30%

35%

40%

45%

20%

7%

2015

27%

28%

2013

6%

34%

22%

2014

10%

32%

18%

2%2016

20%

22%

4%2017

26%

23%

5%

2018H1

28%

March 7, 2019 - Analysts’ meeting

April 25, 2019 - Report for the first three months 2019 Conference call

May 10, 2019 - Annual shareholders' meeting, Lübeck, Germany

August 8, 2019 - Report for the first six months 2019 Conference call

October 30, 2019 - Report for the first nine months 2019 Conference call

Financial calendar 2019

39

40

Melanie Kamann Thomas FischlerCorporate Communications Investor Relations

Drägerwerk AG & Co. KGaA Drägerwerk AG & Co. KGaAMoislinger Allee 53−55 Moislinger Allee 53−5523558 Lübeck, Germany 23558 Lübeck, Germany

Tel +49 451 882-3998 Tel +49 451 882-2685 Fax +49 451 882-3944 Fax +49 451 882-3296Mobile +49 170 8558152 Mobile +49 151 12245295

melanie.kamann@draeger.com thomas.fischler@draeger.comwww.draeger.com www.draeger.com

Contact